Canada Funds K-PAX Study!

Canada Flag

The Canadian HIV Trials Network and the Ontario HIV Treatment Network (OHTN) are funding a double-blind, placebo-controlled randomized clinical trial of K-PAX Immune Support Formula in antiviral-naive HIV-infected patients.

In simple English, this means that a randomized clinical trial is now ongoing to test the ability of K-PAX Immune Support Formula to support the CD4 count of HIV(+) individuals who have not yet started taking antiviral therapy.

Canadian HIV(+) patients with CD4 counts between 350 - 800 CD4 cells who are not yet taking antiviral medications are eligible to participate in this study.

Half the group will receive K-PAX Immune Support Formula and the other half will receive the equivalent of one Centrum vitamin per day.

The endpoints of the study are as follows:

1. To observe if K-PAX Immune Support Formula can significantly slow the decline of the CD4 count in HIV(+) patients who have not yet taken antiviral medications

2. To observe how many patients in each group need to start HAART medications during the 2-year study period.

At the present time, the study is funded to enroll 220 patients at 12 Canadian research centers.  However, additional funding is being sought to expand the sample size to 340 patients as well as to include a study site in the United States.

To enroll in this important study, please contact: Dr. Bill Cameron, The Ottawa Hospital, at (613) 737-8209. This study is open to all patients who are receiving their health care in Canada.

More information will be posted on this website as it becomes available.